- Home
- MDXH vs BEAT Comparison
MDXH vs BEAT Comparison
Compare MDXH & BEAT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MDXH
- BEAT
- Stock Information
- Founded
- MDXH 2003
- BEAT 2015
- Country
- MDXH Belgium
- BEAT United States
- Employees
- MDXH N/A
- BEAT N/A
- Industry
- MDXH
- BEAT Retail: Computer Software & Peripheral Equipment
- Sector
- MDXH
- BEAT Technology
- Exchange
- MDXH Nasdaq
- BEAT Nasdaq
- Market Cap
- MDXH 73.3M
- BEAT 65.4M
- IPO Year
- MDXH 2021
- BEAT 2021
- Fundamental
- Price
- MDXH $1.46
- BEAT $2.00
- Analyst Decision
- MDXH Buy
- BEAT Buy
- Analyst Count
- MDXH 1
- BEAT 1
- Target Price
- MDXH $6.00
- BEAT $8.00
- AVG Volume (30 Days)
- MDXH 88.1K
- BEAT 57.4K
- Earning Date
- MDXH 04-30-2025
- BEAT 03-13-2025
- Dividend Yield
- MDXH N/A
- BEAT N/A
- EPS Growth
- MDXH N/A
- BEAT N/A
- EPS
- MDXH N/A
- BEAT N/A
- Revenue
- MDXH $90,049,000.00
- BEAT N/A
- Revenue This Year
- MDXH $23.38
- BEAT N/A
- Revenue Next Year
- MDXH $16.84
- BEAT N/A
- P/E Ratio
- MDXH N/A
- BEAT N/A
- Revenue Growth
- MDXH 28.29
- BEAT N/A
- 52 Week Low
- MDXH $1.35
- BEAT $1.70
- 52 Week High
- MDXH $3.50
- BEAT $3.48
- Technical
- Relative Strength Index (RSI)
- MDXH 36.94
- BEAT 46.64
- Support Level
- MDXH $1.55
- BEAT $1.85
- Resistance Level
- MDXH $1.66
- BEAT $2.03
- Average True Range (ATR)
- MDXH 0.08
- BEAT 0.11
- MACD
- MDXH 0.00
- BEAT 0.00
- Stochastic Oscillator
- MDXH 21.84
- BEAT 51.35
About MDXH MDxHealth SA
MDxHealth SA is a multinational healthcare company that provides actionable molecular diagnostic information to personalize the diagnosis and treatment of cancer. Its tests are based on proprietary genomic, epigenetic, and other molecular technologies and assist physicians with the diagnosis of urologic cancers, the prognosis of recurrence risk, and prediction of response to a specific therapy. It derives revenues from clinical laboratory service testing or the out-licensing of the company's patented DNA methylation platform and biomarkers. Geographically, it derives revenue from the United States of America (USA), and Europe.
About BEAT Heartbeam Inc.
HeartBeam Inc is a medical technology company primarily focusing on developing and commercializing higher resolution ambulatory Electrocardiogram ("ECG") solutions that enable the detection and monitoring of cardiac disease outside a healthcare facility setting. The Company's ability to develop higher-resolution ECG solutions is achieved through the development of the Company's proprietary and patented Vector Electrocardiography ("VECG") technology platform. The Company has validated this technology and is seeking U.S. Food and Drug Administration ("FDA") clearance for its initial telehealth products.